Letterkenny

Researchers are evaluating a new medicine called NNC6019-0001 for people with transthyretin amyloid cardiomyopathy ATTR-CM, a condition that affects the heart and leads to heart failure. This Phase 3 study compares NNC6019-0001 with a placebo to see if it can reduce the risk of heart-related death and illness. Participants will continue their usual heart treatments throughout the study. Participants will receive either NNC6019-0001 or a matching placebo through intravenous IV infusion. Both groups may also continue their standard heart failure treatments as advised by their doctors. The study is randomized and blinded so that neither participants nor researchers know who receives the medicine or placebo. Treatment and follow-up will last up to about 4 years. During the study, participants will have regular assessments including heart function tests, questionnaires about heart failure symptoms and quality of life, and walking tests to measure physical ability. Researchers will monitor heart-related events such as hospitalizations and urgent visits for heart failure, as well as death from cardiovascular causes. Safety labs and biomarker tests will be done. The main outcome is a combination of cardiovascular deaths and recurrent heart problems measured from the start to the end of the study.

Crohns disease is a chronic condition causing severe inflammation in the digestive tract, mainly affecting the bowels, and leading to symptoms like belly pain, diarrhea, tiredness, and weight loss. This trial is evaluating several targeted therapies for adults with moderate to severe Crohns disease. The study involves around 540 adults and aims to assess how well these treatments work and monitor any side effects over time. The treatments being studied include risankizumab, trosunilimab, lutikizumab, and ABBV-8736. These medicines are given either by injection under the skin or infusion into a vein, depending on the drug. Participants will be randomly assigned to receive one of several treatment combinations or monotherapies, with some continuing risankizumab alone for up to 72 weeks. Participants will attend regular hospital or clinic visits for medical assessments, blood tests, and endoscopies to check the effects of treatment. Researchers will also monitor side effects, collect daily diary information, and use questionnaires. Key outcomes include the percentage of participants achieving endoscopic remission by week 12 and tracking adverse events for up to about 96 weeks.

The trial investigates the safety and effects of MTX-463, an antibody targeting WISP1, in adults aged 40 or older with idiopathic pulmonary fibrosis IPF. This Phase 2a study compares MTX-463 to a placebo, allowing participants to continue approved IPF treatments like pirfenidone, nintedanib, or nerandomilast if stable. Participants must meet specific diagnostic criteria and lung function thresholds to join. Participants receive either MTX-463 or placebo through intravenous infusions every 4 weeks from Day 0 to Week 20. The treatment phase concludes with a visit at Week 24, followed by a safety follow-up at Week 28. Lung function tests including forced vital capacity FVC and lung fibrosis assessments are done at screening, baseline, and during treatment visits. Blood samples are collected regularly to monitor safety and drug levels. Throughout the study, participants attend visits every 4 weeks for assessments of lung function, safety labs, and WISP1 protein levels. The main outcome measures include changes in FVC after 24 weeks and safety profiles over 28 weeks. Participant involvement spans from screening through final safety follow-up, with careful monitoring to evaluate the study drugs impact and tolerability in IPF.